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The Unusual Active Site of Gal6/Bleomycin
Hydrolase Can Act as a Carboxypeptidase,
Aminopeptidase, and Peptide Ligase
members of an increasing family of self-compartmental-
izing or sequestered intracellular proteases (for reviews,
Larsen and Finley, 1997; Lupas et al., 1997).
Direct external access to the active site of Gal6p is
blocked by the C terminus of the protein, which inserts
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and Leemor Joshua-Tor²³
*Center for Biomedical Inventions
Departments of Medicine and Biochemistry
University of Texas-Southwestern Medical Center
Dallas, Texas 75235-8573 into the active site cleft as depicted in Figure 1. The C
terminus is completely conserved in all forms of bleomy-²W. M. Keck Structural Biology Laboratory
Cold Spring Harbor Laboratory cin hydrolase. The core of the Gal6 monomer, including
the active site, is superimposable on the prototypic cys-Cold Spring Harbor, New York 11724
teine protease, papain. Gal6p,however, isan aminopep-
tidase with little substrate sequence specificity (Kam-
bouris et al., 1992; Enenkel and Wolf, 1993; MagdolenSummary
et al., 1993; Zheng et al., 1997), whereas papain is an
endopeptidase with specific substrate preferences, pri-The Gal6 protease is in a class of cysteine peptidases
marily for large hydrophobic residues at the S2 subsiteidentified by their ability to inactivate the anti-cancer
(Schechter and Berger, 1968) (ªSº refers to the proteasedrug bleomycin. The protein forms a barrel structure
subsite and the ªPº to the substrate residues with num-with the active sites embedded in a channel as in the
bers increasing away from the scissile bond). In cellproteasome. In Gal6 the C termini lie in the active site
extracts, Gal6p can account for all the bleomycin hy-clefts. We show that Gal6 acts as a carboxypeptidase
drolase activity.on its C terminus to convert itself to an aminopeptidase
We suspected that the substrate specificity of Gal6pand peptide ligase. The substrate specificity of the pep-
could largely be determined by its unusually positionedtidase activity is determined by the position of the C
and highly conserved C terminus. To investigate thisterminus of Gal6 rather than the sequence of the sub-
possibility, we conducted structural and biochemicalstrate. We propose a model to explain these diverse
studies of Gal6p C-terminal variants. We show that theactivities and Gal6's singular ability to inactivate bleo-
structure and position of the Gal6p C terminus controlsmycin.
the peptidase activity of Gal6p, allowing carboxypepti-
dase, aminopeptidase, endopeptidase, and/or peptide
Introduction ligase activities in different C-terminal variants. The
C-terminal architecture may explain why Gal6p is the
Bleomycin hydrolase is an aminopeptidase originally only enzyme reported to date with the ability to detoxify
discovered by virtue of its ability to hydrolyze the anti- bleomycin. Based on this understanding of the activity
cancer drug bleomycin, thus restricting its clinical use- of Gal6, it may be possible to design inhibitors and
fulness (Akiyama et al., 1981; Lazo and Humphreys, cleavage-resistant bleomycin derivatives for clinical use.
1983). Homologs have been cloned from yeast (Kam-
bouris et al., 1992; Enenkel and Wolf, 1993; Magdolen
Resultset al., 1993; Xu and Johnston, 1994), bacteria (Chapot
et al., 1993), chicken (Adachi et al., 1997), and mammals
The Carboxypeptidase Activity of Gal6p(Takeda et al., 1996), including human (BroÈ mme et al.,
We first investigated Gal6p's apparent carboxypepti-1996; Ferrando et al., 1996). Studies of the yeast form
dase activity. Though the theoretical translation of theof bleomycin hydrolase, Gal6p, have revealed it to be
GAL6 cDNA sequence terminates in a lysine, the crystalan unusual enzyme. The protein negatively regulates the
structure and peptide sequencing of Gal6p show thatgalactose metabolism system and, surprisingly, binds
Lys 454 is missing in the native protein (Joshua-Tor etsingle-stranded DNA and RNA with high affinity (Xu and
al., 1995). To determine whether Gal6p possesses aJohnston, 1994; Zheng et al., 1997). This nucleic acid
carboxypeptidase activity that might be responsible forbinding activity coupled to the hydrolase activity plays
the missing lysine, we solved the structure at 2.05 AÊ ofa role in the detoxification of bleomycin (Zheng and
a Gal6p variant in which the active site cysteine wasJohnston, 1997).
changed to an alanine (C73A), thus destroying the pepti-The crystal structure of Gal6p has been solved
dase activity. We find that the C-terminal amino acid in(Joshua-Tor et al., 1995), revealing two striking features.
this variant, in contrast to the wild-type protein, is lysineFirst, it is a ring, or barrel-like, structure consisting of
(Figure 2A). As evident from the structure (Figure 2A)six monomers that form a channel with an opening of
and cartooned in Figure 2C, the lysine (colored red) nowabout 22 AÊ in diameter and a central cavity of about 45
occupies the P1 position in the binding pocket (FigureAÊ . Second, the six peptidase active sites, one in each
2A). This position is open in the wild-type form (Joshua-monomer, are embedded in the structure such that they
Tor et al., 1995). The C73A variant has no other signifi-are only accessible by substrates through the central
cant variation in structure from the wild-type. The root-channel. Gal6 and the 20S proteasome are founding
mean-square (rms) deviation between the two is 0.39 AÊ
for main chain atoms and 0.95 AÊ for all atoms present
in both structures.³To whom correspondence should be addressed.
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Figure 1. The Structure of the Gal6p Hexamer and Access to the
Active Site
(Top) A space-filling representation of the molecule shown as a side
view with the six subunits shown in different colors. This figure as
well as Figures 2A and 2B were drawn with the program Molscript
(Kraulis, 1991) and rendered with RASTER3D (Bacon and Anderson,
1988; Merritt and Murphy, 1994). The protein is shaped as a cylinder
with a channel through its middle. The channel is approximately 20
AÊ in diameter at the two rims and opens to a larger central cavity.
The C terminus of each subunit folds back into the active site cleft.
(Bottom) A slice through the middle of the protein along it's 3-fold
axis. Four out of the six active sites are shown as distorted stars
and the C terminus as a squiggle line labeled at the end with the
letter C. Access to the active sites is through the central channel.
To cleave Lys 454 from the C terminus, the Ala at
position 453 would have to move to the P1 position
and Lys 454 to the P1' position (Figure 2C). Such a
conformation is exhibited in the structure of a variant
with the active site Cys 73 changed to Ala and the C-ter-
minal Lys 454 deleted genetically. This protein was puri-
fied and the crystal structure solved at 1.87 AÊ . In this
case, as seen in the structure depicted in Figure 2B and
cartooned in Figure 2C, Ala 453 moves to occupy the
P1 position, displacing the Met 367 side chain, which Figure 2. Positioning of the C-Terminal Arm of Gal6 in the Active
is otherwise in the way. This moving forward of the C Site Clefts in the Wild-Type and Mutant Proteins
terminus is apparently allowed by the flexibility of the (A) A superposition of the C-terminal arm and active site residues
glycine at aa450. In the wild-type protein, this glycine of the C73A variant (orange) on the active site cleft region of wild-
type Gal6p (blue). The two C-terminal arms superimpose closelyforms a bulge in the C terminus (G bulge, yellow in Figure
with K454 in the variant clearly seen in red as a well ordered residue2B). In the C73A/DK454 variant, this glycine rotates and
occupying the S1 site and extending from the rest of the chainextends by a screw-like movement, allowing Ala453 to
toward the catalytic residues.
move into the P1 position. Presumably, in the wild-type (B) A similar superposition of the active site cleft region of C73A/
protein this would permit Lys 454 to occupy the P1' DK454 (dark orange) superimposed on the wild-type protein (blue).
position for carboxypeptidase cleavage mediated by A453 extends further toward the catalytic residues in this variant
Cys73. In addition, in this variant one of the carboxylate compared to wild type and is occupying the S1 site. The glycine
bulge of the wild-type protein switches to an extended conformationoxygens of the terminal Ala453 occupies the ªoxyanion
in the variant (yellow).holeº and interacts with glutamine 67 and the amide
(C) Cartoon illustrations of the active site structures of the wild typegroup of alanine 73 (formerly the catalytic cysteine). This
and the variants of Gal6p. Note that the C-terminal residues are
configuration is postulated for the transition state in color-coded in this and following cartoons. The scissors represent
proteolysis and is similar to that found for the cysteine the active site cysteine and histidine at the cleavage site. In the
protease inhibitor, leupeptin (Schroder et al., 1993). The Gal6 cartoon, the uncolored ovals represent the residues from the
P1, P1', and P2' position of a peptide substrate.other carboxylate oxygen interacts with the catalytic
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by flexing it such that Lys454 isplaced in the P1' position
for cleavage. The glycine at 450 is crucial for this exten-
sion and precise cleavage. Once the lysine is removed,
the C terminus retracts to place the now C-terminal
alanine 453 at the S2 site. This processing in some ways
resembles that of the Sindbid virus core protein, which
also self-cleaves to leave its C terminus in the active
site. However, in this latter case the processing is a
single event, which yields an inactive enzyme (Tong et
al., 1993).
The C Terminus of Gal6p Defines
Its Substrate Specificity
The processing and the resulting positioning of the Gal6
C terminus implies that the C terminus itself is an impor-
tant factor in determining the activity of the enzyme.
Examination of the structure of the Gal6p active site
suggests that the C terminus could serve two roles. The
carboxylate of Ala453 could interact with the N terminus
Figure 3. G450A Has a Different Processing Pattern from the Wild- of a peptide substrate and anchor it in the active site.
Type Protein
In addition, the C terminus could act as a ªmolecular
An electrospray mass spectrometry shows G450A protein cleaving
rulerº to restrict the active site to aminopeptidase rathereither one or three residues of the C terminus.
than endopeptidase activity.
To explore the role of the carboxylate, we altered the
N terminus of the substrate. We found that Gal6p ishistidine (His 369). In the C73A variant the lysine carbox-
active as an aminopeptidase on Lys-AMC (Lys-7-amido-ylate is in the same position. Since the oxyanion hole
4-methylcoumarin [Bachem], a fluorogenic substratebinds negatively charged oxygens, it is not surprising
serving as a dipeptide analog) (Kcat 5 19.3/s, Km 5 228that one of the carboxylate oxygens in each of these
mM). However, when the acetylated form of this sub-variants would tend to bind there. This does not occur
strate, Ac-Lys-AMC, is used, there is a dramatic loss ofin the wild-type protein, possibly due to repulsion and/
activity (Kcat 5 0.59/s, Km 5 243 mM). This neutralizationor steric hindrance by the sulfhydryl group of the active-
of the N-terminal charge of the substrate leads to a 50-site cysteine.
fold decline in Kcat with little or no effect on Km. Similar
results were obtained using other pairs of acetylatedThe G Bulge Is Involved in Accurate
and nonacetylated substrates (data not shown). TheseAutocatalytic Processing of K454
results imply that the carboxylate interacts with the NA prediction of the mechanism we propose for pro-
terminus of the substrate and positions it by ionic inter-cessing of the Gal6p C terminus is that the inherent
actions relative to the nucleophilic cysteine.torsion angle flexibility of Gly 450 plays a critical role
in allowing correct positioning of the C terminus for
carboxypeptidase activity. To test this prediction, we Converting Gal6p from Aminopeptidase
to Endopeptidasechanged Gly450 to Ala genetically. We predicted that
this alteration would modify the flexibility of the C termi- To investigate our proposed molecular ruler function of
the C terminus, we made a series of Gal6p C-terminalnus and therefore affect its normal processing. The
G450A variant was purified from Escherichia coli and deletions. Gal6D2 is a genetic deletion of Lys454 and
Ala453, Gal6D3 deletes in addition Leu452, and Gal6D4the molecular mass determined by electrospray mass
spectrometry (Figure 3). A minority of the protein has also deletes Ala451. Each of these proteins was purified
from E. coli and is presumed to have an intact structurethe mass (53,997 Da) corresponding to Gal6p lacking
the C-terminal lysine. However, the majority of the pro- as each had normal DNA binding activity (data not
shown). If indeed the substrate specificity of Gal6p istein has the mass 53,813 Da corresponding to removal
of the three C-terminal residues, Lys454, Ala453, and determined by the position of the C-terminal carboxyl-
ate, we predict that these variants would lose the abilityLeu452 (Figure 3). Therefore, Gly450 is crucial in ob-
taining the correct distance between the anchoring car- to act on diamino-peptides and possibly become endo-
peptidases, since the anchoring carboxylate would po-boxylate and the nucleophilic cysteine. Interestingly, the
protease cleaves between residues 451 and 452 but sition these short substrates too far from the nucleo-
phile. As predicted, all three deletion variants have nonot between leucine 452 and alanine 453. Since the
polypeptidechain in that region is in an extended confor- detectable activity on the short Arg-AMC or Lys-AMC
substrates. However, each of the deletions had activitymation with the amide carbonyl groups alternating in
opposite directions, only one direction is appropriate on the longer Ala-Arg-AMC substrate (Kcat/KmD2 5 1/s/
mM, Kcat/KmD3 5 3.2/s/mM, Kcat/KmD4 5 1.6/s/mM), al-for nucleophilic attack by the cysteine sulfhydryl group,
thus explaining why there is no detectable cleavage beit with a 40- to 100-fold lower Kcat than the wild-type
protein on Arg-AMC (KcatD2 5 0.31/s, KcatD3 5 1.3/s,between residues 452 and 453.
We conclude that Gal6p processes its own C terminus KcatD4 5 1.69/s).
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Figure 4. Mass Spectrometry Shows that
Deletion of the C-Terminal Residues of Gal6p
Changes Its Substrate Specificity
A 12 mer peptide was used as the substrate.
The peptide sequence and the cleavage sites
are indicated at thetop of the picture (arrows).
The mass of the 12 mer has been framed. (A)
Gal6p. (B) Deletionof C-terminal two residues
Gal6D2. (C) Deletion of C-terminal three resi-
dues Gal6D3. (D) Deletion of C-terminal four
residues Gal6D4. In (A), (B), and (C), the peaks
labeled by stars are ligation products re-
sulting in an increase of mass over that of the
original substrate.
We also tested the wild-type and variant proteins nal substrate. For example, Gal6D3 produces products
against a more natural substrate, a 12 amino acid resi- that are larger by two amino acid increments, in addition
due peptide. The products were analyzed by mass spec- to the products that are two amino acids shorter, which
trometry and showed that the wild-type protein created are discussed above (Figure 4C). Indeed, on careful
products that decreased by one amino acid sequentially analysis the wild-type protein also produces a longer
(Figure 4A). This activity is a manifestation of aminopep- peptide in one amino acid increments (Figure 4A). Ap-
tidase activity, as a time-course analysis of the products parently, Gal6 and its C-terminal variants also have pep-
shows 11 mers evident first and shorter peptides accu- tidyl ligase activity. This activity implies that in the initial
mulating at later time points (data not shown). In contrast acylation step the fragment N terminus to the scissile
to the wild-type protein, Gal6D2 (Figure 4B) and Gal6D3 bond forms a relatively stable thioester intermediate
(Figure 4C) cleave this substrate two amino acids at a with the enzyme. The C-terminal fragment must then be
time, and the Gal6D4 (Figure 4D) cleaves the 12 mer released so that new substrate can enter and be en-
three amino acids at a time. That Gal6D2 and Gal6D3 gaged in the transferase activity.
cleave at one of the same positions and that Gal6D2
has a minor product resulting from a single amino acid
cleavage probably arise from the restrictions on the Increased Sensitivity of C-Terminal Deletion
hinge movement noted above. The results with both the
Mutant of Gal6p to Leupeptinartificial and natural substrates indicate that the deletion
If the active site is left open by the C-terminal deletions,of C-terminal amino acids from Gal6p changes wild-
one prediction is that these endopeptidases would betype Gal6 from an aminopeptidase to an endopeptidase
sensitive to the inhibitor, leupeptin. As shown in Figurewith cleavage of a particular peptide bond on the sub-
5, the wild-type Gal6 protein is not sensitive to leupeptin,strate depending on its distance from the C terminus of
consistent with the observation that the C terminus oc-the enzyme rather than its surrounding sequence. Thus,
cupies part of the position leupeptin would need to bindthe enzyme has positional specificity created by its par-
the active site (see Figure 4 in Joshua-Tor et al., 1995).ticular placement of the C terminus.
In striking contrast, the Gal6D3 protein activity on the
Ala-Arg-AMC substrate is sensitive to the inhibitor (Fig-The Peptide Ligase Activity of Gal6p
ure 5). These results provide a molecular explanationand Its Variants
for the resistance of Gal6p to leupeptin; the processedIn the course of the studies using the 12 mer peptide
carboxyl terminus of Gal6p protects the active site fromsubstrate, we noted, surprisingly, that the deletion mu-
tants produced products that were larger than the origi- inhibition.
Gal6p C Terminus Controls Its Activities
107
Figure 6. Possible Mechanism of Bleomycin Hydrolysis by Bleomy-
cin Hydrolase
substrate, which can be anchored to the C-terminal car-
boxylate of Gal6; the carbon the amino group is bound
to can then be considered to be the a-carbon of the
first residue, with a chirality identical to an L-amino acid,
and the amide bond that is hydrolyzed is the first peptide
bond, which is cleaved in an aminopeptidase reaction.
The rest of the bleomycin molecule could be considered
as the ªside chain.º The chirality is such that this rather
large side chain would point into the large cavity in the
center of the Gal6 hexamer, just as would the side chain
of the amino-terminal residue of any other peptide sub-
strate. This view of how bleomycin is hydrolyzed may
be useful in designing forms of the drug that are resistant
Figure 5. Deletion of the C Terminus of Gal6p Results in an Increase to hydrolysis.
of Its Sensitivity to Leupeptin Another consequence of positional rather than se-
(Top) Relative inhibition of wild-type and Gal6D3p by leupeptin on quence specificity is the ability to engineer variants with
Arg-AMC and Ala-Arg-AMC substrates, respectively. altered substrate specificity simply by changing the dis-
(Bottom) A cartoon illustrating the rationale for the increased sensi-
tance of the C terminus from the active site cysteine.tivity of deletions of the C terminus to leupeptin by opening subsites
Consistent with this observation, it was recently shownpreviously occupied by the C-terminal residues.
that deletion of the C-terminal residue of the bacterial
bleomycin hydrolase, PepC, confers altered peptidase
Discussion activity (Mata et al., 1997). In addition, two GAL6 homo-
logs were recently cloned from Lactobacillus delbrueckii,
In most enzymatic processes, substrate specificity oc- pepG and pepW, which have shorter C termini (WDSLA/I
curs through clefts and crevices on the enzyme, which vs. WDPMGALA for yeast). Endopeptidase activity was
are lined with side chains or backbone groups that are demonstrated for PepG (Klein et al., 1997). These obser-
complementary to the substrate. Based on the results vations are consistent with the model presented here.
of the experiments reported here, we present a different The organization and processing of Gal6p resembles
form of peptidase activity where substrate specificity is that of the proteasome (Joshua-Tor et al., 1995; LoÈ we
modulated by the positioning of Gal6p's own C terminus et al., 1995). Not only is the overall architecture similar
in the active site as opposed to the features of the with a channel leading to a large internal cavern, but,
substrate. It appears that the negatively charged C ter- like Gal6p, the proteasome self-processes to activate
minus of the enzyme anchors the positively charged its peptidase activity (Chen and Hochstrasser, 1996;
amino terminus of a peptide substrate through ionic Seemuller et al., 1996). For Gal6p, the proteosome, and
other self-compartmentalizing proteases (Larsen andinteractions. The site of cleavage is controlled by the
Finley, 1997; Lupas et al., 1997), it may be advantageousdistance of this C terminus from the nucleophilic active
to sequester a nonspecific protease activity by spatialsite residue as it acts as a molecular ruler to confer
constraints while achieving some processivity by en-positional specificity.
closing several catalytic centers within a single cavity.One of the important implications of this model may
In addition, several of these self-compartmentalizingbe of clinical relevance, since it can be directly applied
proteases do not belong to the classic families of aspar-to bleomycin hydrolysis. Gal6p is apparently the only
tate, serine, cysteine, or metalloproteases, and thosepeptidase that can detoxify bleomycin in mammalian
that do have unusual features as we have demonstrated(Lazo and Chabner, 1996) and yeast (Xu and Johnston,
for the C terminus in Gal6p and its involvement in sub-1994) cells. However, the C-terminal deletion variants of
strate recognition. Clearly, there is much to discoverGal6p do not detoxify bleomycin (Zheng and Johnston,
about this structural class of proteases.unpublished data). Both of these observations may be
explained by the positional specificity model. The amide
Experimental Proceduresbond of bleomycin that is hydrolyzed by Gal6p is on the
b-aminoalanine moiety of the metal-binding region of Plasmid
the drug (Figure 6). We can consider the primary amino The production of wild-type and C73A Gal6 proteins has been re-
ported previously (Zheng et al., 1997). To construct C73A/DK454group of this moiety as the ªamino terminusº of the
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mutant, the primer ActII-GAL6 (59-AAAAACCATGGCCTCTTCATCG mm Mar Research imaging plate detector system and integrated
and scaled as for C73A. In this case, a total of 199,974 reflectionsATA-39) was used along with the primer GAL6(-LYS) (59-AGAGCTGC
TGAAACTATTTAGGCCAAAGCACCCATTGGGT-39) to obtain the were collected, 49,450 unique with 98.8% completeness at 35.0±
1.87 AÊ resolution (96.5% in the last shell 1.94±1.87 AÊ ). The Rmerge forC73A/DK454 gene fragment by PCR using C73A gene fragment as
a template. The resulting fragment was cloned into pKM260 as this data set is 4.2% (6.2% for the last shell).
described previously (Zheng et al., 1997). The following oligonucleo-
tides were used to delete the C-terminal residues of Gal6p. Three Structure Determination
The structure of the C73A mutein was solved by isomorphous re-primersÐG6del2aa (59-CGGGATCCAGTTACAAAGCACCCATTGGG
TCC-39), G6del3aa, (59-CTGAAACTATTTAAGCACCCATGGGGTC placement using the wild-type protein structure (Protein Data Bank
[PDB] code: 1GCB) with cysteine 73 changed to an alanine andCCA-39), and G6del4aa (59-CGGGATCCAGTTAACCCATTGGGTCC
CAGAT-39)Ðwere used with primer ActII-GAL6 (59-AAAAACCATGG excluding all solvent atoms. The initial Rcryst was 0.372 with an R-free
(using 10% of the data) of 0.385. Rigid body refinement at 8±3CCTCTTCATCGATA-39) to delete the C-terminal two, three, and four
AÊ was followed by steps of positional refinement using X-PLORresidues by PCR. The resulting fragments were digested by Nco1
(BruÈnger, 1988) with increasing resolution with iterative model build-and BamH1 and cloned into the BamH1/Nco1 site of pKM260 to
ing using the program O (Jones et al., 1991). Lysine 454 appearedform plasmids pWZ-BLHD2, pWZ-BLHD3, and pWZ-BLHD4. The
very clearly in the electron density map and was added to the model.plasmids were transformed into E.coli strain BL21 to express pro-
In addition, clear density appeared for five residues N-terminal toteins. The G450A mutant was made by PCR GAL6 gene fragment
residue 1 belonging to the TEV cleavage site, which is part of theusing the oligonucleotide MutGly (59-CGCGGATCCCGCTATTTATTT
histidine tag used for this construct. These were added to the modelGGCCAAAGCAGCCATTGGGTCC-39) and primer ActII-GAL6. The
as well. The final model was refined to 2.05 AÊ with a crystallographicresulting fragment was digested by BamH1/Nco1 and cloned into
R factor of 0.193 and free R of 0.257 with 3700 nonhydrogen proteinpKM260.
atoms, 370 water molecules, and 6 sulfates. No s cutoff was used.
The rms deviation from ideality is 0.011 AÊ for bond lengths, 1.8338Protein Expression and Purification
for bond angles, 21.68 for dihedral angles, and 1.448 for impropers.For structure studies, mutant proteins were expressed in E. coli
More than 90% of the (φ, c) angles of the model are in the mostusing a histidine tag followed by a TEV cleavage site at the N termi-
favored regions, and all residues are in allowed regions of the Rama-nus. Purification to homogeneity was accomplished using Ni-NTA
chandran plot (Laskowski et al., 1993). The C-terminal region is verybeads (Qiagen) followed by an anion exchange HQ perfusion chro-
clear in the electron density maps. Coordinates were deposited inmatography column on a Sprint system (PerSeptives Biosystems).
the PDB code 1a6r.The proteins for enzyme assays were prepared as follows: the
The structure of C73A/DK was solved and refined in much theE. coli strain BL21 was transformed with the appropriate plasmids
same way as described for C73A. The structure was refined to 1.87for protein production. The resulting strains were grown in 2 ml
AÊ to a crystallographic Rcryst of 0.173 and free R of 0.217 with rmscultures at 378C overnight, each containing 25 mg/ml of ampicillin
deviation from ideality of 0.012 AÊ for bond lengths, 1.7228 for bondand chloramphenicol. Each culture then was inoculated into 1 liter
angles, 21.28 for dihedral angles, and 1.3108 for impropers. Theof L-broth with the same antibiotics and grown to O.D. 5 0.6±1.0.
electron density is very clear in the region of the C terminus hereIPTG was added to a final concentration of 200 mg/ml. Cells were
as well. There are 420 water, 2 glycerol, and 5 sulfate molecules ingrown for another 12 hr at 168C and then harvested. Proteins were
the model. In this case more than 92% of the (φ, c) angles of thepurified using Ni-NTA resin following the standard protocol by Qia-
model are in the most favored of the Ramachandran plot and nonegen. Each protein from Ni-NTA beads was extensively dialyzed
in disallowed regions. Coordinates were deposited in the PDB codeagainst Buffer A (25 mM Tris-HCl [pH 8.5], 10% glycerol, 50 mM
3gcb.KCl, 1 mM EDTA, 7 mM 2-Mercaptoethanol) and applied to a Bio-
Scale Q5 column (BioRad) that had been equilibrated with Buffer
Enzyme AssayA. The column was washed with 3±4 column volumes of Buffer A
Gal6p protease activity was assayed with the synthetic substratebefore the protein was eluted with a 0±0.5M KCl gradient in Buffer
Arg-AMC (Bachem) under the condition as previously describedA. The peak fractions were pooled, dialyzed against Buffer A, and
(Xu and Johnston, 1994). Enzyme kinetic studies of Gal6p were
concentrated by Centricon 30 (Amicon). The protein was stored in
accomplished on a luminescence spectrometer LS50-B (Perkin-
this buffer plus 50% glycerol at 2208C.
Elmer). The excitation and emission wave lengths were 360 nm and
460 nm. The excitation and emission slit width were both 5 mm.
Crystallization Each assays has been repeated at least three times. The range of
Crystals of C73A were grown by the sitting drop vapor diffusion substrate concentration used was 0.1- to 4-fold of Km. The rate of
method. Equal amounts of a 20 mg/ml protein solution with 0.5 mM each reaction was determined by least square fit. The Kcat and km
bleomycin in 25 mM Tris buffer (pH 8.5) were mixed with a reservoir were obtained by Eadie-Scatchard plot.
solution containing 10% PEG 4K, 0.45 M (NH4)2SO4 in 0.1 M Tris (pH The inhibition of leupeptin on Gal6p and the C-terminal three
9.0). Crystals are of space group P6322 with one monomer in the residue deletion mutein were assayed under the same condition as
asymmetric unit. The cell dimensions are a 5 b 5 150.68, c 5 90.16. above except that 6 nM of the enzyme was used. For Gal6p, 100
Crystals of the C73A/DK454 mutant protein were grown using the mM of Arg-AMC was used, and for the mutantprotein, 100 mM of Ala-
hanging drop vapor diffusion method. In this case, equal amounts Arg-AMC was used. Protein was incubated with different amount of
of a 10 mg/ml protein solution with 0.5 mM bleomycin in 25 mM leupeptin for 20 min at 48C before being assayed at 308C.
Tris buffer (pH 8.5) were mixed with a reservoir solution containing The peptide cleavages by Gal6p and the mutant proteins were
0.5 M (NH4)2SO4, 3% PEG monomethyl ether 2K in Tris (pH 8.5). The assayed as follows: in a 20 ml reaction (50 mM KH2PO4, 50 mM
cell dimensions for these crystals are a 5 b 5 150.55, c 5 90.13 Na2HPO4 [pH 7.5], 8 mM EDTA, 10 mM DTT), 2±10 mg of Gal6p (2
and are of the same space group. mg for Gal6p, 10 for deletion mutein) was mixed with 4 mM of 12
mer peptide. Reactions were incubated at 308C for 1 hr (for Gal6p)
Data Collection and Processing or 2±4 hr for deletion mutant proteins. Two microliters of the reaction
A data set from a single crystal of C73A was collected at 90 K at mixture was add to 200 ml of MALDI matrix buffer (50% acetone
beamline X12B at the NationalSynchrotron LightSource at Brookha- nitrile 1 0.1% TFA) to stop the reaction. One microliter of which
ven National Laboratories using a 300 mm Mar Research imaging was used to measure the molecular mass by Matrix Assisted Laser
plate detector system and integrated and scaled with the HKL pack- Desorption Ionization Time-of-Flight (MALDI-TOF) on Voyager DE
age (Otwinsowski, 1993). A total of 367565 reflections, 37272 unique (PerSeptive Biosystems).
with 97.3% completeness in the range 50.0±2.05 AÊ (99.2% in the
last shell 2.12±2.05 AÊ ) were collected. The Rmerge for this data set is Acknowledgments
7.7% (16.4% for the last shell).
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